Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)

NCT07224763 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT07224763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)
Lead sponsor
United Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 30, 2026
Completion date
November 30, 2076
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esrd (end-stage renal disease), kidney transplantation, xenotransplantation